Efficacy of dabigatran for dissolving deep vein thromboses in outpatients with a deteriorated general condition: A single center experience

International Heart Journal

Volumn 56, Issue 4, 2015, Pages 395-399

  Fujino, Tadashi ^a   Yamazaki, Yukiko ^a   Yamazaki, Akiko ^a   Kabuki, Takayuki ^a   Kiuchi, Shunsuke ^a   Kobayashi, Kenzaburo ^a   Yamazaki, Junichi ^a   Ikeda, Takanori ^a  

^a TOHO UNIVERSITY   (Japan)

Author keywords

Non vitamin K antagonist oral anticoagulant; Thrombosis dissolution

Indexed keywords

D DIMER; DABIGATRAN; ANTICOAGULANT AGENT; BENZIMIDAZOLE DERIVATIVE; BETA ALANINE;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DRUG EFFICACY; ECHOGRAPHY; EPISTAXIS; FEMALE; FOLLOW UP; HUMAN; LUNG EMBOLISM; MALE; MENTAL DISEASE; NEOPLASM; ORAL BLEEDING; OUTPATIENT; PARTIAL THROMBOPLASTIN TIME; PREDICTIVE VALUE; PRIORITY JOURNAL; RECEIVER OPERATING CHARACTERISTIC; SENSITIVITY AND SPECIFICITY; TREATMENT RESPONSE; ANALOGS AND DERIVATIVES; ATRIAL FIBRILLATION; COMPLICATION; DOSE RESPONSE; HEALTH DISPARITY; JAPAN; MIDDLE AGED; ORAL DRUG ADMINISTRATION; PATHOPHYSIOLOGY; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

ADMINISTRATION, ORAL; AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HEALTH STATUS DISPARITIES; HUMANS; JAPAN; MALE; MIDDLE AGED; NEOPLASMS; OUTPATIENTS; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; VENOUS THROMBOSIS;

EID: 84936995030     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.14-399     Document Type: Article

References (27)

1. Camm AJ, Lip GY, De Caterina R, et al. 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 2012; 33: 2719-47.
2. Morita S, Ajiro Y, Uchida Y, Iwade K. Dabigatran for left atrial thrombus. Eur Heart J 2013; 34: 2745.
3. Hammerstingl C, Pötzsch B, Nickenig G. Resolution of giant left atrial appendage thrombus with rivaroxaban. Thromb Haemost 2013; 109: 583-4.
4. Nagamoto Y, Shiomi T, Matsuura T, et al. Resolution of a left ventricular thrombus by the thrombolytic action of dabigatran. Heart Vessels 2014; 29: 560-2.
5. Dobashi S, Fujino T, Ikeda T. Use of apixaban for an elderly patient with left atrial thrombus. BMJ Case Rep 2014. (in press)
6. Schulman S, Kearon C, Kakkar AK, et al; RE-COVER Study Group. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-52.
7. Eriksson BI, Dahl OE, Rosencher N, et al; RE-MODEL Study Group. Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
8. *). A randomised, double-blind, non-inferiority trial. Thromb Haemost 2011; 105: 721-9.
9. Prins MH, Lensing AW, Bauersachs R, et al; EINSTEIN Investigators. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J 2013; 11: 21.
10. Nitta D, Mitani H, Ishimura R, et al. Deep vein thrombosis risk stratification. Int Heart J 2013; 54: 166-70.
11. Watanabe A, Yamashita N, Yamashita T. Blood stasis secondary to heart failure forms warfarin-resistant left atrial thrombus. Int Heart J 2014; 55: 506-11.
12. Committee for Proprietary Medicinal Products (CPMP). Points to Consider on Clinical Investigation of Medicinal Products for Prophylaxis of Intra- and Post-Operative Venous Thrombpembolic Risk. The European Agency for the Evaluation of Medical Products, 2000; London: CPMP/EWP/707/98. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003304.pdf accessed on March 13, 2015.
13. Yasaka M, Yamaguchi T, Miyashita T, Tsuchiya T. Regression of intracardiac thrombus after embolic stroke. Stroke 1990; 21: 15404.
14. Marcu CB, Kramer C, Donohue TJ. Giant left atrial thrombus successfully treated with anticoagulation. Heart Lung Circ 2007; 16: 55-6.
15. Takasugi J, Yamagam H, Okata T, Toyoda K, Nagatsuka K. Dissolition of the left atrial appendage thrombus with rivaroxaban therapy. Cerebrovasc Dis 2013; 36: 322-3.
16. Varin R, Mirshahi S, Mirshahi P, et al. Whole blood clots are more resistant to lysis than plasma clots--greater efficacy of rivaroxaban. Thromb Res 2013; 131: e100-9.
17. Niemann M, Gaudron PD, Bijnens B, et al. Differentiation between fresh and old left ventricular thrombi by deformation imaging. Circ Cardiovasc Imaging 2012; 5: 667-75.
18. Blom JW, Doggen CJ, Osanto S, Rosendaal FR. Malignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA 2005; 293: 715-22.
19. Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ 3rd. Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med 2000; 160: 809-15.
20. Hutten BA, Prins MH, Gent M, Ginsberg J, Tijssen JG, Büller HR. Incidence of recurrent thromboembolic and bleeding complications among patients with venous thromboembolism in relation to both malignancy and achieved international normalized ratio: a retrospective analysis. J Clin Oncol 2000; 18: 3078-83.
21. Prandoni P, Lensing AW, Piccioli A, et al. Recurrent venous thromboembolism and bleeding complications during anticoagulant treatment in patients with cancer and venous thrombosis. Blood 2002; 100: 3484-8.
22. Elting LS, Escalante CP, Cooksley C, et al. Outcomes and cost of deep venous thrombosis among patients with cancer. Arch Intern Med 2004; 164: 1653-61.
23. Lyman GH, Khorana AA, Falanga A, et al. American Society of Clinical Oncology guideline: recommendations for venous thromboembolism prophylaxis and treatment in patients with cancer. J Clin Oncol 2007; 25: 5490-505. (Review)
24. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Com erota AJ. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 2008; 133: 454S-545S.
25. Hamanaka S, Kamijo Y, Nagai T, et al. Massive pulmonary thromboembolism demonstrated at necropsy in Japanese psychiatric patients treated with neuroleptics including atypical antipsychotics. Circ J 2004; 68: 850-2.
26. Pampallona S, Bollini P, Tibaldi G, Kupelnick B, Munizza C. Combined pharmacotherapy and psychological treatment for depression: a systematic review. Arch Gen Psychiatry 2004; 61: 7149. (Review)
27. Lieberman JA, Stroup TS, McEvoy JP, et al; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23.